1. A Phase 1/2 Trial of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Thai Infants
- Author
-
PHRAMONGKUTKLAO HOSPITAL BANGKOK (THAILAND), Watanaveeradej, V., Kerdpanich, A., Samakoses, R., Tanakijaru, K., Aree, C., Simasathien, S., Mammen, M. P., Nisalak, A., Hengprasert, S., Jarman, R. J., Gibbons, R. V., Innis, B. L., Hutagalung, Y., Chunsuttiwat, S., Sun, W., Endy, T. P., Thomas, S., Eckels, K. H., Putnak, R., Vaughn, D. W., PHRAMONGKUTKLAO HOSPITAL BANGKOK (THAILAND), Watanaveeradej, V., Kerdpanich, A., Samakoses, R., Tanakijaru, K., Aree, C., Simasathien, S., Mammen, M. P., Nisalak, A., Hengprasert, S., Jarman, R. J., Gibbons, R. V., Innis, B. L., Hutagalung, Y., Chunsuttiwat, S., Sun, W., Endy, T. P., Thomas, S., Eckels, K. H., Putnak, R., and Vaughn, D. W.
- Abstract
The Walter Reed Army Institute of Research (WRAIR) has produced a tetravalent live-attenuated dengue vaccine that has been well tolerated and immunogenic in U.S. adults and Thai children. As infants are considered by many as an important age group for vaccination in dengue-endemic countries, we evaluated the vaccine in Thai flavivirus-na ve infants who are at risk for dengue., See also ADM002075., The original document contains color images. Presented at the Army Science Conference (25th) held in Orlando, FL on 27-30 November 2006.
- Published
- 2006